Bruker Corp. (NASDAQ:BRKR)
The Company designs, manufactures, services and markets analytical and life science systems and associated products to address the needs of its customers in life science research, pharmaceutical, biotechnology and molecular diagnostics research.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
High Volume breakout on 02/19/13
Recs
Brkr 1-9, Brkr 1-9, 50% insider ownership. Gityer 20 in there.
Recs
Future potential
Recs
Good growth over market..
Recs
11/22/2010 IBD #96
Recs
This is one of my STARZ.
Here is the thought process on this STAR:
a) Divided rate over Zero
b) 3 Year Beta between -5 & +3
c) 15% + Insider ownership
d) No greater than -50% Growth rate for the last 3 years (tought= last couple of years so goo that insiders are still owning the stocks)
e) Current CAPS rating between 3 Stars & 5 Stars
Open to all Industries and Sectors screened this down to just 250 stocks. I like round numbers. 12 of them I already own through other screening tools. I tend to be somewhat conservative but looking for 3 things at this point in my investing:
1. Stability & Strength
2. Yield and Modest Growth
3. Strong Position within a sector regardless of whether the entire sector is strong or not. Each sector has to perform to some degree for the whole world economy to function. I am looking for 5 or more years down the road, ROI, and Growth.
Not looking for rockets, just stars. This is a Star!!
Recs
Good growth and earnings ahead.
Recs
An outstanding R&D program; partnered with many international companies; on the leading edge of development in several product areas.
Recs
Bounced back down from its recent run. At PE of 18, this looks solid.
Recs
Recs
Continued development of superb products and outstanding marketing along with joint development agreements will help PUSH Bruker
Recs
Award winning analytical equipment manufacturer. Pioneer and leader in solid EDX products. Top engineering management team. Significant and continuing management stock buy in shows confidence. Excellent earnings forecast. Acquiring successful compatible companies as well as focused internal growth.
Recs
The fact that stem cell research is now again legal in the US is encouraging. And I saw on the scorecard that other members have outperformed with this stock even above $7.00 so it looks like a good time to buy & hold this stock.
Recs
THIS IS A VERY INTERESTING STOCK. I AM GOING TO WATCH THIS ONE CAREFULLY & LET YOU KNOW WHEN I AM GOING TO JUMP IN. HAS TAKEN A DRASTIC BEATING UNDERPERFORMING THE S&P
Recs
in at 4.15, my amateur analysis says this stock belongs between 7.5-10 within next 2 years if not 1.
Recs
I bought in on BRKR, ROE is good.
Recs
Good growth and future earnings.
Recs
Obama = Healthcare
Recs
Recs
Biotech stock punished for missing 1st Q 2008 earnings will rebound in the next Q and beyond.
Solid fundamentals.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 37 : 1 2 Next »